Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting
  • Home
  • Search results for: 'research area metabolism cyp3a cyp450'

Search results for: 'research area metabolism cyp3a cyp450'

Items 31-40 of 58

Page
per page
  1. Apremilast (CC-10004)
    A4317 Apremilast (CC-10004)
    Target: Phosphodiesterases (PDEs)
    Summary: PDE4 inhibitor
      ≥23.05 mg/mL
  2. Sildenafil Citrate
    A4321 Sildenafil Citrate
    Target: Phosphodiesterases (PDEs)
    Summary: Treat erectile dysfunction and PAH
      ≥25.35 mg/mL
  3. Tadalafil
    A4327 Tadalafil
    Target: Phosphodiesterases (PDEs)
    Summary: PDE5 inhibitor
      insoluble in H2O; insoluble in EtOH; ≥16.6 mg/mL
  4. Rolipram
    A4328 Rolipram
    Target: Phosphodiesterases (PDEs)
    Summary: PDE4-inhibitor and an anti-inflammatory agent
      insoluble in H2O; ≥13 mg/mL
  5. CPI-613
    A4333 CPI-613
     1 Citation
    Target: Pyruvate dehydrogenases (PDH)
    Summary: PDH/α-KGDH inhibitor
      insoluble in H2O; ≥19.45 mg/mL
  6. S- (+)-Rolipram
    A4349 S- (+)-Rolipram
    Summary: CAMP-specific PDE4 inhibitor
      insoluble in H2O; ≥13.9 mg/mL
  7. Varespladib (LY315920)
    A4356 Varespladib (LY315920)
    Target: Phospholipases
    Summary: HnsPLA inhibitor,potent and selective
  8. Anacetrapib (MK-0859)
    A4375 Anacetrapib (MK-0859)
     1 Citation
    Target: CETP
    Summary: RhCETP/mutant CETP(C13S) inhibitor
      ≥31.9 mg/mL
  9. Evacetrapib (LY2484595)
    A4377 Evacetrapib (LY2484595)
    Target: CETP
    Summary: CETP inhibitor,potent and selective
      ≥32.1 mg/mL
  10. Lonafarnib
    A4379 Lonafarnib
    Target: FPTase
    Summary: Ftase inhibitor,potent and selective
      ≥31.95 mg/mL

Items 31-40 of 58

Page
per page
Shop By
Now Shopping by
  1. Category Signaling Pathways Remove This Item
  2. Reported Experiments Animal Experiments Remove This Item
Clear All
Shopping Options
Category
  1. Proteases 1 item
  2. Metabolism 51item
  3. DNA Damage/DNA Repair 1 item
  4. PI3K/Akt/mTOR Signaling 1 item
  5. Microbiology & Virology 1 item
  6. Stem Cell 1 item
  7. Membrane Transporter/Ion Channel 1 item
  8. Endocrinology and Hormones 1 item
  9. Neuroscience 2item
  10. Others 1 item
Specificity
  1. Selective 42item
  2. Non-Selective 1 item
Reversibility
  1. Reversible 1 item
  2. Irreversible 4item
Target
  1. Acyl coenzyme A: cholesterol acyltransferases 1 item
  2. Factor Xa 1 item
  3. Phosphodiesterases (PDEs) 10item
  4. RARs 1 item
  5. Estrogen and Related Receptors 1 item
  6. Stearoyl-CoA 9-desaturase (SCD-1) 1 item
  7. AMPK 1 item
  8. Cytochrome P450 (CYP450) 4item
  9. HMG-CoA Reductases 3item
  10. SGLT 1 item
  11. DGAT 2item
  12. Insulin and Insulin-like Receptors 1 item
  13. Pyruvate dehydrogenases (PDH) 1 item
  14. CETP 2item
  15. Fatty-acid-binding proteins (FABPs) 1 item
  16. Folate Analogue 1 item
  17. Nampt 1 item
  18. Carbonic Anhydrases 3item
  19. Histamine H1 Receptors 1 item
  20. Phospholipases 1 item
  21. Catechol O-Methyltransferase (COMT) 1 item
  22. Hydroxylases 1 item
  23. ATGL 1 item
  24. FPTase 1 item
  25. PPAR 1 item
  26. FAAH 1 item
  27. carnitine reabsorption 1 item
  28. TRPC channel 1 item
Related Disease
  1. Acne 1 item
  2. Acute Kidney Injury 1 item
  3. Bladder Cancer 1 item
  4. Bladder Carcinoma 1 item
  5. Brain Injuries Studies 1 item
  6. Breast Cancer 5item
  7. Cancer 13item
  8. Cervical Cancer 1 item
  9. Cocaine-Related Disorders 1 item
  10. Diabetes 1 item
  11. Dyslipidemia 2item
  12. Erectile Dysfunction 3item
  13. HIV 1 item
  14. Hypercholesterolemia 2item
  15. Inflammation 1 item
  16. Inflammatory Diseases 2item
  17. Kidney Injury Studies 1 item
  18. Leukemia 2item
  19. Lung Cancer 2item
  20. Lymphoma 3item
  21. Melanoma 2item
  22. Neuroblastoma 3item
  23. Neurocognitive Disorders 1 item
  24. Obsessive-Compulsive Disorder 1 item
  25. Prostate Cancer 2item
  26. Psoriasis 2item
  27. Psoriasis Vulgaris 1 item
  28. Pulmonary Arterial Hypertension 1 item
  29. Rheumatoid Arthritis 2item
  30. Schizophrenia 2item
  31. Type 2 Diabetes 4item